Hospice Care

Business

AstraZeneca Shifts Gears: Full NYSE Listing Marks Strategic Pivot to US Market

The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.

Feb 2, 2026

Business

Beyond the Hype: Separating Market Momentum from Sustainable Value

While several stocks have posted impressive short-term gains, a closer look reveals a divergence between fleeting catalysts and fundamental strength. We analyze one surging name with a solid foundation and two others where caution may be warranted.

Feb 2, 2026

Business

IAC Earnings Preview: Can the Digital Media Giant Reverse Its Slump?

As IAC prepares to report quarterly results, investors are bracing for another potential revenue decline. We examine the key metrics, peer performance, and what the numbers could mean for the company's turnaround strategy.

Feb 2, 2026

US

Prosecutor's Family Link to Kirk Shooting Scene Sparks Conflict-of-Interest Battle in Utah Court

As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.

Feb 2, 2026

Business

Early-Stage Drilling Hits Broad Mineralization at Troubadour's Senneville Project in Quebec

Initial drill results from the Senneville gold-silver-copper property in Quebec's prolific Val-d'Or camp have intersected significant near-surface mineralization, with intervals up to 57.8 meters, marking a promising start to the multi-phase exploration campaign.

Feb 2, 2026

Business

Immunocore's Valuation Puzzle: Short-Term Volatility Masks Long-Term Promise

Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.

Feb 2, 2026

Business

Market Momentum or Mirage? Three High-Flying Stocks That May Be Overheated

While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.

Feb 2, 2026

Business

Cash Flow Kings and Question Marks: One Stock to Watch, Two to Approach with Caution

While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.

Feb 2, 2026

Business

Cash Flow Kings and Question Marks: One Stock to Watch, Two to Approach with Caution

While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

ABIVAX Shares Surge on Takeover Buzz and Pipeline Progress, Despite CEO Denials

ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.

Feb 2, 2026

Business

Eli Lilly Doubles Down: $3.5 Billion Bet on Next-Gen Obesity Drugs and Gene Therapy Partnerships

Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.

Feb 2, 2026

Business

Beyond the Headlines: Three Middle Eastern Small-Caps Poised for Growth Amid Market Volatility

While geopolitical tensions have rattled regional markets, a closer look reveals resilient smaller companies in the GCC and Turkey offering unique value propositions. We analyze three firms with market caps under $900 million in the education, packaging, and industrial sectors.

Feb 2, 2026

World

Thailand's Political Survivor: Anutin Charnvirakul's Canny Path to Power Faces Voter Test

As Thailand heads to the polls, Prime Minister Anutin Charnvirakul—a master political operator known for his ability to navigate crises—seeks to retain power. His tenure has been marked by strategic reversals, controversial policies, and the delicate balancing of conservative elites and public expectations.

Feb 2, 2026

Business

Beyond Humira: How AbbVie Plans to Reign as a Biopharma Powerhouse by 2031

With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.

Feb 2, 2026

Business

Beyond Luxury: How Airline Turmoil Is Fueling a Surge in Private Jet Demand

A wave of commercial flight disruptions is pushing a new class of travelers toward private aviation, not for opulence but for reliability. We examine the shifting calculus of air travel and what a seat actually costs.

Feb 2, 2026

World

Bangladesh Court Sentences Ex-PM Hasina to Decade in Prison, UK MP Niece Also Convicted in Land Scandal

A special anti-corruption court in Dhaka has delivered a landmark verdict, sentencing former Prime Minister Sheikh Hasina to 10 years imprisonment and her British lawmaker niece to four years over illicit land allocations in a flagship housing project. The ruling intensifies the political turbulence ahead of crucial elections.

Feb 2, 2026

World

Shutdown Showdown: Speaker Johnson Navigates ICE Debate and Funding Impasse

With a partial government shutdown underway, House Speaker Mike Johnson confronts a dual crisis: securing passage of a federal funding package and mediating an intensifying political battle over the scope and tactics of Immigration and Customs Enforcement operations.

Feb 2, 2026

Business

Takeda Lifts Full-Year Forecasts and Launches New PID Therapy, But Investor Debate on Valuation Intensifies

Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.

Feb 2, 2026

Business

February's Investment Spotlight: Three Stocks Poised for Growth in 2026

As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.

Feb 2, 2026